News

HTX-011, which is a combination of local anesthetic bupivacaine and anti-inflammatory meloxicam, had produced statistically significant reductions in both pain intensity and need for opioids through 72 hours post-surgery.

With funding from the DoD, Bavarian Nordic will utilize its proprietary MVA-BN platform to develop a vaccine against various strains of the virus, for which there is currently

The approval was based on data from the Phase III PATH (Polyneuropathy And Treatment with Hizentra) study, which is the largest controlled clinical study in CIDP patients to date. CIDP is a

As per the agreement terms, Lundbeck will pay an upfront amount of around DKK750m (€100m). The company is further required to pay up to DKK6bn (€805m) to Prexton in development,

The study showed that ALXN1210 achieved non-inferiority to Soliris (eculizumab) in complement inhibitor treatment-naïve patients with PNH based on the co-primary endpoints of transfusion avoidance and normalization of

ZW49 was developed by leveraging ZymeLink in combination with Zymeworks’ flagship Azymetric bispecific platform. The Company expects to file an Investigational New Drug (IND) application this year in order

This follows the FDA’s acceptance in February 2018 of an Investigational New Drug (IND) Application by the Company for the potentially ground-breaking drug. Fast Track Designation is one

Akcea, which is an affiliate of Ionis, is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with serious rare diseases. Inotersen is

Foghorn initially commenced operations in 2016, and developed a Gene Traffic Control product platform to discover and develop drugs based on insights into the chromatin regulatory system that